| abstract |
The present disclosure is based on trimethylene carbonate (TMC) having a molar fraction of polylactic acid (PLA) and / or polyglycolic acid (PGA) used to deliver a bioactive agent to a target site. Injectable formulations containing degradable polymers are intended. Excipients such as polyethylene glycol (PEG) can be added to the formulation to reduce injectability and / or control the release of bioactive agents. Biodegradable polymers suitable for use in injectable formulations include D, L-PLA: TMC, D-PLA: TMC, L-PLA: TMC, TMC: PLA: PGA and variations thereof. . In addition, TMC and PLA copolymers and TMC: PLA: PGA terpolymers can be formed into nanoparticles and delivered to target sites with injectable crosslinkable polyethylene glycol systems. In at least one embodiment, injectable formulations are used to treat eye diseases. |